Download Files:
AZ194
$220 – $1,350
Products Details
Product Description
– AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects[1].
Web ID
– HY-145169
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C34H31F2N3O3
References
– [1]Cai S, et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Sci Transl Med. 2021;13(619):eabh1314.
CAS Number
– 2241651-99-8
Molecular Weight
– 567.63
Compound Purity
– 99.79
SMILES
– O=C(N1CCC(CC1)C2=NC3=C(N2CC4=CC(F)=CC=C4)C=CC=C3)C5=CC=C(C(OC)=C5)OCC6=CC(F)=CC=C6
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 33.33 mg/mL (ultrasonic)
Target
– Sodium Channel
Isoform
– Nav1.7
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
